Sophia Abene

Results in about 5.5 to 6 hours, employing advanced technology to detect bacterial growth and minimum inhibitory concentration.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.

As the WHO seeks Emergency Use Listing for new diagnostics due to rising cases in the Democratic Republic of the Congo, 50,000 doses of this vaccine will be donated to Central Africa.

This week, MP Biomedicals launched rapid diagnostic tests for gastrointestinal pathogens, Invivyd's monoclonal antibody pemivibart shows an 84% reduction in symptomatic COVID-19 risk, Nestlé is acquiring global rights to the Vowst therapy for CDI, and more.

Approved for individuals aged 12 years and older, this vaccine features a monovalent component and replaces the previous Novavax formula.

The most recent National Healthcare Safety Network annual survey shows that 78% of US hospitals now have sepsis committees, an increase from 73% in 2022.

The FDA, CDC, and state health departments have been monitoring foodborne illnesses this August including Listeria, Salmonella, and Clostridium botulinum.

As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.

MP Biomedicals’ tests detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.

The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.

Two recent CDC Morbidity and Mortality Weekly Report (MMWR) studies show stable overall vaccination rates for 2023 but a decline in HPV vaccination rates for certain birth cohorts.

Nestlé aims to increase the global availability of Vowst, an FDA-approved therapy indicated for a healthcare-associated infection, while also seeking new opportunities for the product worldwide.

This virus is known for causing mild illness and the distinctive "slapped cheek" rash in children and has recently shown an unusual increase in activity.

This week, Pfizer-BioNTech's Phase 3 trial of a COVID-19 and influenza combination vaccine yielded mixed results, mpox as a global health emergency emphasizes need for coordinated international response, ongoing challenges with MRSA infections, and more

The study found that vancomycin is more effective than metronidazole in achieving event-free survival for C difficile infections across all infection severity levels.

The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.

The NIH’s RECOVER Initiative has developed new symptom indices for Long COVID in school-age children and adolescents to find 14 symptoms overlapping between the two groups.

This study provides evidence that using DAAs reduces liver fibrosis and improves clinical outcomes.

In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.

The study found that the vaccine, combined with presumptive antimalarial treatment, reduced Plasmodium falciparum parasitaemia and clinical malaria over two transmission seasons.

Mpox virus evades the innate immune system by interfering with antiviral pathways signaling and interferon responses, increasing replication, and complicating outbreak management, especially in non-endemic regions.

Recent study establishes that the generic glecaprevir/pibrentasvir is bioequivalent to the brand name version, offering the same therapeutic benefits.

NOWDiagnostics' represents a new option for early syphilis detection and aligns with ongoing efforts to improve STI screening.

The declaration was based on the outbreak's severity compared to past events and the differences between mpox Clade I and Clade II, which affect response strategies.

The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.

Results reveal that the antiviral did not significantly improve lesion resolution in mpox patients compared to placebo, but it did report a lower mortality rate among participants than that seen in the broader DRC cases.

Jeffery Silber MD, highlights VE303's consistent formulation as an advantage over traditional fecal transplants and discusses how the trial's patient-centric approach aims to improve outcomes and reduce healthcare-associated infections.

In part 2 of this interview with Deborah Birx, MD, she highlights that ActivePure Technology provides a continuous decontamination solution that operates independently of manual intervention to reduce HAIs.

Addressing this threat requires the development of effective vaccines and therapeutics specifically targeting evolving H5N1 viruses.

Study highlights that many long-term symptoms may result from ongoing inflammation rather than persistent viral presence.